Evidence Hub

P-1340. Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates From Patients with Diabetic Foot Infection in the United States and Europe (2017–2023)

M. Huband, Marisa L Winkler, Kelley A. Fedler, M. Castanheira

Open Forum Infectious Diseases, 2026

Abstract

Abstract Background Delafloxacin (DLX) is a fluoroquinolone antibacterial with oral and intravenous treatment options approved in ≥50 countries for treatment of acute bacterial skin and skin structure infection or community-acquired pneumonia in adults. Indicated organisms in the United States (US) include: staphylococci (S. aureus [SA] both MSSA and MRSA, S. haemolyticus and S. lugdunensis), streptococci (S. pyogenes, S. agalactiae and S. anginosus group), Enterococcus faecalis (EF), Enterobacterales (Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae species complex) and Pseudomonas aeruginosa (PSA).The in vitro activity of DLX, ciprofloxacin (CIP), levofloxacin (LEV), moxifloxacin (MOX), minocycline and meropenem-vaborbactam were determined against bacterial isolates from patients with diabetic foot infection (DFI) in the US and Europe (EUR). Methods Isolates from patients with DFI were collected in the SENTRY Surveillance Program (2017–2023) from sites in the US and EUR. Broth microdilution MIC testing was conducted according to CLSI methods. CLSI, EUCAST, and FDA breakpoint criteria (2025) were applied. Isolate identifications were determined at the collection site and confirmed using MALDI-TOF MS (as needed). Results The most common DFI pathogens were SA (35.7%), Enterobacterales (33.4%), PSA (9.8%), streptococci (9.0%) and EF (4.7%). Overall, 87.5% (FDA) of SA isolates from patients with DFI in the US were susceptible to DLX (including 96.7% of MSSA and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free